oxybutynin has been researched along with Urination Disorders in 59 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "6 mg/kg oxybutynin daily resulted in improvement of lower urinary tract symptoms, quality of life and maximum flow rate in most patients with Williams-Beuren syndrome." | 9.16 | The effects of oxybutynin on urinary symptoms in children with Williams-Beuren syndrome. ( Bruschini, H; de Bessa, J; Gomes, CM; Honjo, RS; Kim, CA; Pinheiro, MS; Sammour, ZM; Srougi, M; Trigo-Rocha, FE, 2012) |
| "The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence." | 7.68 | [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990) |
| "Seventy girls and 27 boys with clinically diagnosed OAB and urge incontinence were randomly allocated to placebo, oxybutynin, or bladder training (branch I), and 89 girls and 16 boys with clinically diagnosed DV to either cognitive treatment or pelvic floor training (branch II)." | 5.19 | Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. ( Bachmann, H; Bael, A; de Jong, TP; Hirche, H; Hjälmås, K; Hoebeke, P; Jodal, U; John, U; Lax, H; Misselwitz, J; Nijman, RJ; Tamminen-Möbius, T; van Gool, JD; Walle, JV; Winkler-Seinstra, P, 2014) |
| "6 mg/kg oxybutynin daily resulted in improvement of lower urinary tract symptoms, quality of life and maximum flow rate in most patients with Williams-Beuren syndrome." | 5.16 | The effects of oxybutynin on urinary symptoms in children with Williams-Beuren syndrome. ( Bruschini, H; de Bessa, J; Gomes, CM; Honjo, RS; Kim, CA; Pinheiro, MS; Sammour, ZM; Srougi, M; Trigo-Rocha, FE, 2012) |
| "Oxybutynin hydrochloride (Pollakisu tablets) was administered at a daily dose of 6 or 9 mg to 75 elderly patients with urinary tract disorders, including neurogenic bladder and unstable bladder, with chief complaints of pollakisuria, urgency on urination and urinary incontinence." | 5.07 | [Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly]. ( Hisazumi, H; Nakajima, K; Nihino, A; Uchibayashi, T, 1991) |
| "The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence." | 3.68 | [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990) |
| "Oxybutynin has statistically significant effects on subjective symptoms and objective urodynamic parameters in patients with detrusor hyperactivity compared to propantheline." | 2.67 | Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. ( Bunke, B; de Geeter, P; Ebner, A; Faber, P; Hannappel, J; Heidler, H; Madersbacher, H; Melchior, H; Schäfer, W; Thüroff, JW, 1991) |
| " New antimuscarinic anticholinergic medications have improved the treatment of OAB, offering patients efficacy equal to that of immediate-release oxybutynin with fewer side effects and an improved dosing schedule." | 2.42 | Overactive bladder: improving the efficacy of anticholinergics by dose escalation. ( MacDiarmid, SA, 2003) |
| " Controlled drug delivery systems seen in commercially available OAB formulations alter the pharmacokinetics of antimuscarinic medications in ways that maintain efficacy and allow once-daily dosing and reduction of adverse events." | 2.41 | New perspectives on the overactive bladder: pharmacokinetics and bioavailability. ( Gupta, S; Mori, T; Sathyan, G, 2002) |
| " Despite short terminal disposition half-lives of 2-3 and 3-4 hours for tolterodine and its active 5-hydroxy metabolite, respectively, twice/day dosing is effective due to the drug's prolonged pharmacodynamic effects." | 2.40 | Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. ( Guay, DR, 1999) |
| " Pharmacokinetic studies have indicated a slow rise in mean plasma concentration of the isomer R-oxybutynin for 4 to 6 hours after a single dose of OROS oxybutynin, followed by maintenance of steady concentrations for up to 24 hours, minimizing the fluctuations between peak and trough associated with TID dosing of 5-mg immediate-release oxybutynin tablets." | 2.40 | An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. ( Goldenberg, MM, 1999) |
| "Oxybutynin ER was well tolerated in all the trials, with adverse events usually being mild to moderate and transient." | 1.32 | Oxybutynin extended-release: a review of its use in the management of overactive bladder. ( Perry, CM; Scott, LJ; Siddiqui, MA, 2004) |
| "Propiverine is a drug for the treatment of incontinence and pollakiuria." | 1.30 | [Effects of propiverine hydrochloride (propiverine) on isolated rat and dog urinary bladder]. ( Kaneko, S; Nakano, D; Nishimori, T; Ohara, M, 1999) |
| "Propiverine is a drug for the treatment of incontinence and pollakiuria." | 1.30 | [Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs]. ( Hirota, T; Isogai, M; Kaneko, S; Nagao, M; Shimizu, H, 1999) |
| " The results of the study argue against the dosage regimen proposed before these adverse events were detected." | 1.29 | Plasma levels of oxybutynine chloride in children. ( Autret, E; Averous, M; Bertiere, MC; Couet, W; Dutertre, JP; Jonville, AP; Robert, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (20.34) | 18.7374 |
| 1990's | 22 (37.29) | 18.2507 |
| 2000's | 21 (35.59) | 29.6817 |
| 2010's | 4 (6.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Gool, JD | 1 |
| de Jong, TP | 1 |
| Winkler-Seinstra, P | 1 |
| Tamminen-Möbius, T | 1 |
| Lax, H | 1 |
| Hirche, H | 1 |
| Nijman, RJ | 1 |
| Hjälmås, K | 1 |
| Jodal, U | 1 |
| Bachmann, H | 1 |
| Hoebeke, P | 1 |
| Walle, JV | 1 |
| Misselwitz, J | 1 |
| John, U | 1 |
| Bael, A | 1 |
| Fukata, A | 1 |
| Yamazaki, T | 1 |
| Romero, P | 1 |
| Rodríguez, E | 1 |
| Muñoz, M | 1 |
| Delucchi, A | 1 |
| Guerrero, JL | 1 |
| Lillo, AM | 1 |
| Cano, F | 1 |
| Matilde Osses, S | 1 |
| Romero, MI | 1 |
| Gonzalez Roca, C | 1 |
| Sammour, ZM | 1 |
| Gomes, CM | 1 |
| de Bessa, J | 1 |
| Pinheiro, MS | 1 |
| Kim, CA | 1 |
| Honjo, RS | 1 |
| Trigo-Rocha, FE | 1 |
| Bruschini, H | 1 |
| Srougi, M | 1 |
| Appell, RA | 3 |
| Lai, HH | 1 |
| Boone, TB | 1 |
| Newman, DK | 1 |
| Giovannini, D | 1 |
| Gupta, S | 1 |
| Sathyan, G | 1 |
| Mori, T | 1 |
| Staskin, DR | 2 |
| Dmochowski, RR | 2 |
| Wimett, L | 1 |
| Laustsen, G | 1 |
| Rovner, ES | 1 |
| Wein, AJ | 1 |
| Scarpero, HM | 1 |
| MacDiarmid, SA | 1 |
| Smith, DA | 1 |
| Siddiqui, MA | 1 |
| Perry, CM | 1 |
| Scott, LJ | 1 |
| Marschall-Kehrel, D | 1 |
| Johnson, TM | 1 |
| Burgio, KL | 1 |
| Redden, DT | 1 |
| Wright, KC | 1 |
| Goode, PS | 1 |
| Gacci, M | 1 |
| Del Popolo, G | 1 |
| Macchiarella, A | 1 |
| Celso, M | 1 |
| Vittori, G | 1 |
| Lapini, A | 1 |
| Serni, S | 1 |
| Sandner, P | 1 |
| Maggi, M | 1 |
| Carini, M | 1 |
| Applebaum, SM | 1 |
| Nasrallah, PF | 1 |
| Simon, JW | 1 |
| Moisey, CU | 2 |
| Stephenson, TP | 2 |
| Brendler, CB | 2 |
| Bary, PR | 1 |
| Cochat, P | 1 |
| Meunier, P | 1 |
| Di Maio, M | 1 |
| Autret, E | 1 |
| Jonville, AP | 1 |
| Dutertre, JP | 1 |
| Bertiere, MC | 1 |
| Robert, M | 1 |
| Averous, M | 1 |
| Couet, W | 1 |
| Taniguchi, K | 1 |
| Tsubaki, K | 1 |
| Mizuno, H | 1 |
| Take, K | 1 |
| Okumura, K | 1 |
| Terai, T | 1 |
| Shiokawa, Y | 1 |
| Kasabian, NG | 1 |
| Vlachiotis, JD | 1 |
| Lais, A | 1 |
| Klumpp, B | 1 |
| Kelly, MD | 1 |
| Siroky, MB | 1 |
| Bauer, SB | 1 |
| Sugiyama, T | 1 |
| Matsuda, H | 1 |
| Oonishi, N | 1 |
| Kiwamoto, H | 1 |
| Esa, A | 1 |
| Park, YC | 1 |
| Kurita, T | 1 |
| Uchida, A | 1 |
| Kunikata, S | 1 |
| Frankenburg, FR | 1 |
| Kando, JC | 1 |
| Centorrino, F | 1 |
| Gilbert, JM | 1 |
| Bensman, A | 1 |
| Deschenes, G | 1 |
| Audry, G | 1 |
| Grapin, C | 1 |
| Szollar, SM | 1 |
| Lee, SM | 1 |
| Kelleher, CJ | 1 |
| Cardozo, LD | 1 |
| Khullar, V | 1 |
| Salvatore, S | 1 |
| Abrams, P | 1 |
| Freeman, R | 1 |
| Anderström, C | 1 |
| Mattiasson, A | 1 |
| Amarenco, G | 1 |
| Marquis, P | 1 |
| McCarthy, C | 1 |
| Richard, F | 1 |
| Guay, DR | 1 |
| Kaneko, S | 2 |
| Nakano, D | 1 |
| Ohara, M | 1 |
| Nishimori, T | 1 |
| Nagao, M | 1 |
| Hirota, T | 1 |
| Isogai, M | 1 |
| Shimizu, H | 1 |
| Goldenberg, MM | 1 |
| Yamao, Y | 1 |
| Kawauchi, A | 1 |
| Tanaka, Y | 1 |
| Watanabe, H | 1 |
| Kitamori, T | 1 |
| Imada, N | 1 |
| Shirakawa, S | 1 |
| Clarke, B | 1 |
| Movig, KL | 1 |
| Egberts, AC | 1 |
| Lenderink, AW | 1 |
| Leufkens, HG | 1 |
| Sand, P | 1 |
| Dmochowski, R | 1 |
| Anderson, R | 1 |
| Zinner, N | 1 |
| Lama, D | 1 |
| Roach, M | 1 |
| Miklos, J | 1 |
| Saltzstein, D | 1 |
| Boone, T | 1 |
| Albrecht, D | 1 |
| Soomro, NA | 1 |
| Khadra, MH | 1 |
| Robson, W | 1 |
| Neal, DE | 1 |
| Cannon, TW | 1 |
| Chancellor, MB | 1 |
| Garely, AD | 1 |
| Burrows, LJ | 1 |
| Finkbeiner, AE | 1 |
| Bissada, NK | 1 |
| Welch, LT | 1 |
| Uchibayashi, T | 1 |
| Nakajima, K | 1 |
| Nihino, A | 1 |
| Hisazumi, H | 1 |
| Thüroff, JW | 1 |
| Bunke, B | 1 |
| Ebner, A | 1 |
| Faber, P | 1 |
| de Geeter, P | 1 |
| Hannappel, J | 1 |
| Heidler, H | 1 |
| Madersbacher, H | 1 |
| Melchior, H | 1 |
| Schäfer, W | 1 |
| Yamauchi, K | 1 |
| Ohashi, K | 1 |
| Osanai, H | 1 |
| Inagaki, N | 1 |
| Yamaguchi, S | 1 |
| Hashimoto, H | 1 |
| Yachiku, S | 1 |
| Moore, KH | 2 |
| Hay, DM | 1 |
| Imrie, AE | 1 |
| Watson, A | 1 |
| Goldstein, M | 1 |
| Sutherst, JR | 1 |
| Holmes, DM | 1 |
| Montz, FJ | 1 |
| Stanton, SL | 1 |
| LeWitt, P | 1 |
| Goto, M | 1 |
| Kato, K | 1 |
| Kondo, A | 1 |
| Otani, T | 1 |
| Takita, T | 1 |
| Kobayashi, M | 1 |
| Kirkali, Z | 1 |
| Whitaker, RH | 1 |
| Aubert, D | 1 |
| Cencig, P | 1 |
| Royer, M | 1 |
| Takimoto, Y | 1 |
| Kiyotaki, S | 1 |
| Kawazoe, K | 1 |
| Fuse, T | 1 |
| Kitamura, K | 1 |
| Yamamoto, T | 1 |
| Satoh, Y | 1 |
| Okada, K | 1 |
| Kishimoto, T | 1 |
| Mundy, AR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial[NCT04909047] | 120 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Transvaginal Electrical Stimulation for the Treatment of OAB-dry[NCT04957524] | 24 participants (Anticipated) | Interventional | 2021-12-20 | Recruiting | |||
| A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder[NCT01640002] | Phase 1 | 42 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for oxybutynin and Urination Disorders
| Article | Year |
|---|---|
Pharmacologic treatment for detrusor overactivity.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2002 |
The overactive bladder: a nursing perspective.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cost of Illness; Cr | 2002 |
New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Biological Availability; Chol | 2002 |
Future studies of overactive bladder: the need for standardization.
Topics: Adult; Child; Cholinergic Antagonists; Female; Forecasting; Humans; Mandelic Acids; Muscarinic Antag | 2002 |
Oxytrol approved for overactive bladder.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Drug Approval; Humans; Mandelic Acids; United S | 2003 |
Update on overactive bladder: pharmacologic approaches on the horizon.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Adrenergic beta-3 Rec | 2003 |
Muscarinic receptors: what we know.
Topics: Animals; Central Nervous System; Heart; Humans; Mandelic Acids; Muscarinic Antagonists; Muscle, Smoo | 2003 |
Overactive bladder: improving the efficacy of anticholinergics by dose escalation.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Dose-Response Relationship, Drug; Humans; Ma | 2003 |
Overactive bladder. Strategies for better recognition and management.
Topics: Behavior Therapy; Benzhydryl Compounds; Biofeedback, Psychology; Cresols; Diagnosis, Differential; E | 2004 |
Update on nocturia: the best of rest is sleep.
Topics: Behavior Therapy; Deamino Arginine Vasopressin; Female; Humans; Male; Mandelic Acids; Quality of Lif | 2004 |
Pharmacologic agents in micturitional disorders.
Topics: Baclofen; Bethanechol Compounds; Dantrolene; Dicyclomine; Ephedrine; Flavoxate; Guanethidine; Humans | 1980 |
[Enuresis and benign micturition disorders in childhood. I. Diagnosis and management].
Topics: Child; Deamino Arginine Vasopressin; Enuresis; Humans; Mandelic Acids; Urination Disorders | 1995 |
[Bladder dysfunction in children].
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Mandelic Acids; Parasympatholytic | 1995 |
Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Drug Evaluation; H | 1999 |
An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
Topics: Cholinergic Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Mandelic Aci | 1999 |
Pharmacotherapy of the overactive bladder and advances in drug delivery.
Topics: Administration, Intravesical; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Botulinum Toxi | 2002 |
Current pharmacotherapeutic strategies for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-Action Preparations; Humans; Mandeli | 2002 |
Uropharmacology: part VI. Parasympathetic depressants.
Topics: Acetylcholine; Atropine; Belladonna Alkaloids; Benactyzine; Cyclohexanes; Hemicholinium 3; Humans; M | 1977 |
17 trials available for oxybutynin and Urination Disorders
| Article | Year |
|---|---|
Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Mandelic Acids | 2014 |
The effects of oxybutynin on urinary symptoms in children with Williams-Beuren syndrome.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hu | 2012 |
Effects of behavioral and drug therapy on nocturia in older incontinent women.
Topics: Aged; Aged, 80 and over; Behavior Therapy; Biofeedback, Psychology; Female; Humans; Mandelic Acids; | 2005 |
Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunc | 2007 |
The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mi | 1980 |
The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mi | 1981 |
Intravesical oxybutynin for spinal cord injury patients.
Topics: Adult; Aged; Cholinergic Antagonists; Humans; Injections; Mandelic Acids; Middle Aged; Spinal Cord I | 1996 |
Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Double-Blind Method; Female; Hu | 1998 |
[Quality of life of women with stress urinary incontinence with or without pollakiuria].
Topics: Adult; Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Prospective Studies; Quality | 1998 |
Anticholinergic medication for the unstable bladder: prospective trials of imipramine/propantheline versus penthienate and oxybutynin versus penthienate.
Topics: Adrenergic Uptake Inhibitors; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Method; Drug | 1996 |
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Drug Administ | 2001 |
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability.
Topics: Adult; Aged; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Age | 2001 |
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability.
Topics: Adult; Aged; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Age | 2001 |
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability.
Topics: Adult; Aged; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Age | 2001 |
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability.
Topics: Adult; Aged; Cross-Over Studies; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Age | 2001 |
[Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly].
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged; Paras | 1991 |
Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Mandelic Acid | 1991 |
Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability.
Topics: Double-Blind Method; Female; Humans; Mandelic Acids; Middle Aged; Parasympatholytics; Urinary Bladde | 1990 |
Response to treatment of detrusor instability in relation to psychoneurotic status.
Topics: Colonic Diseases, Functional; Double-Blind Method; Enuresis; Female; Humans; Life Change Events; Man | 1990 |
Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial.
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Mandelic Ac | 1989 |
24 other studies available for oxybutynin and Urination Disorders
| Article | Year |
|---|---|
Comparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction.
Topics: Animals; Female; Imidazoles; Mandelic Acids; Muscarinic Antagonists; Rats; Urethral Obstruction; Uri | 2016 |
Voiding dysfunction: another etiology of vulvovaginitis in young girls.
Topics: Adolescent; Biofeedback, Psychology; Child; Child, Preschool; Colposcopy; Female; Humans; Mandelic A | 2011 |
Treatment of overactive bladder: the Antimuscarinic Clinical Effectiveness Trial.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2002 |
Skin patch approved for treatment of overactive bladder.
Topics: Drug Delivery Systems; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Urination Disorders | 2003 |
Oxybutynin extended-release: a review of its use in the management of overactive bladder.
Topics: Administration, Oral; Animals; Delayed-Action Preparations; Double-Blind Method; Drug Administration | 2004 |
Reflux and voiding abnormalities in children.
Topics: Counseling; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imipramine; Male; Mandelic | 1984 |
Plasma levels of oxybutynine chloride in children.
Topics: Adolescent; Aging; Body Weight; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; Paras | 1994 |
Agents for the treatment of overactive detrusor. VI. Synthesis and pharmacological properties of acetamide derivatives bearing cyclic amines in N-substituents.
Topics: Acetamides; Animals; In Vitro Techniques; Mandelic Acids; Muscle Contraction; Muscle, Smooth; Mydria | 1994 |
The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.
Topics: Administration, Intravesical; Adult; Child; Child, Preschool; Follow-Up Studies; Humans; Mandelic Ac | 1994 |
[Anticholinergic therapy of urinary incontinence and urinary frequency associated with the elderly--with special reference to dementia].
Topics: Aged; Aged, 80 and over; Butylamines; Dementia; Drug Administration Schedule; Drug Therapy, Combinat | 1993 |
Bladder dysfunction associated with clozapine therapy.
Topics: Adult; Clozapine; Deamino Arginine Vasopressin; Enuresis; Female; Humans; Male; Mandelic Acids; Para | 1996 |
A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.
Topics: Adult; Aged; Aged, 80 and over; Cholinergic Antagonists; Exercise Therapy; Female; Humans; Incontine | 1997 |
[Effects of propiverine hydrochloride (propiverine) on isolated rat and dog urinary bladder].
Topics: Acetylcholine; Animals; Atropine; Benzilates; Butylamines; Dogs; Dose-Response Relationship, Drug; E | 1999 |
[Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs].
Topics: Animals; Atropine; Benzilates; Binding, Competitive; Butylamines; Cerebral Cortex; Dogs; Dose-Respon | 1999 |
Systematic treatment for nocturnal urinary frequency following a sleep-micturition chart.
Topics: Aged; Benzilates; Cholinergic Antagonists; Circadian Rhythm; Female; Humans; Hypnotics and Sedatives | 1999 |
Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinergic Antagonists; Drug Prescriptions; Drug Uti | 2001 |
Detrol LA and Diropan XL for overactive bladder.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Clinical Trials as Topic; Cresols; Delayed-Action Pre | 2001 |
[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
Topics: Administration, Oral; Drug Administration Schedule; Drug Evaluation; Humans; Mandelic Acids; Polyuri | 1990 |
Hyperhidrosis and hypothermia responsive to oxybutynin.
Topics: Body Temperature; Humans; Hyperhidrosis; Hypothermia; Mandelic Acids; Urination Disorders | 1988 |
[Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Child | 1988 |
The use of oxybutynin in urological practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Combined Modality Therapy; Fema | 1987 |
[Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children].
Topics: Adolescent; Child; Child, Preschool; Circadian Rhythm; Female; Humans; Imipramine; Male; Mandelic Ac | 1986 |
[Clinical effectiveness of KL 007 (oxybutynin hydrochloride) in urinary disorders].
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Male; Mandelic Acids; Manometry; Middle Ag | 1985 |
The unstable bladder.
Topics: Female; Humans; Imipramine; Mandelic Acids; Propantheline; Psychotherapy; Urinary Bladder; Urinary B | 1985 |